Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study

Conclusion:The concomitant HBsAg declines and ALT elevations indicate that a single, very low dose of IMC-I109V elicited on-target activity consistent with the TCR bispecific (ENVxCD3) mechanism of action, without adverse events.These results are encouraging for the prospect of identifying a tolerable and active treatment regimen with higher and repeat dosing.Enrolment in Part 1 dose escalation continues to evaluate this novel mechanism designed to eliminate HBV-positive hepatocytes.(Eudract no.